Christopher G. Bunick, MD, PhD, is editor in chief of Dermatology Times and an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut.
Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.
Panelists discuss how IL-17 is a key pro-inflammatory cytokine in plaque psoriasis pathogenesis. It stimulates keratinocyte proliferation, promotes neutrophil recruitment, induces antimicrobial peptides, and up-regulates other inflammatory mediators, creating a self-perpetuating inflammatory cascade in lesional skin.
Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.
Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.
Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.
Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.
Dematology Times' Editor in Chief interviews Adelaide Hebert, MD, who will be honored at the AAD 2025 Legacy Celebration for her impact on pediatric dermatology.
Many patients, especially parents of pediatric patients, exhibit steroid phobia, impacting treatment adherence.
Long-term safety data suggests that JAK inhibitors have a lower risk of cardiovascular and thromboembolic events than previously thought.
Medical and aesthetic dermatologists partner at SBS 2025 to bridge gaps between clinical care and cosmetic procedures.
Compliance with acne medications remains a challenge, but timely intervention can prevent severe skin damage.
Maximize your AAD 2025 experience with expert tips on education, networking, and navigating the exhibit hall in Orlando.
Christopher Bunick, MD, PhD, is an associate professor of dermatology and physician-scientist at Yale School of Medicine in New Haven, Connecticut.
Join Dermatology Times’ quarterly editor in chief Christopher Bunick, MD, PhD, as he discusses transformative advances in psoriasis care.
Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.
Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.
At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.
Christopher Bunick, MD, PhD, reviews the latest findings on benzene in benzoyl peroxide, highlighting the importance of proper storage and patient safety.
Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.
Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.
Key opinion leaders examine upadacitinib's role in managing atopic dermatitis and its impact on improving patients' quality of life.
Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.
Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.
Medical experts examine the practical application of clinical study results to real-world atopic dermatitis management strategies.
Atopic dermatitis experts evaluate the integration of composite scores and quality of life measures as a new benchmark for comprehensive disease management.
Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.
By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief in atopic dermatitis.
Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.
